SAVE THE DATE - PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, will be hosting a FREE webinar session relating to the long anticipated final guidelines published by the Patented Medicine Prices Review Board (PMPRB). The webinar will take place ... Read More


Bryan Ferguson, Editor, Insights Within 1-2 weeks, 1 million people laid off in March will begin to lose their health benefits.Laid-off patients who previously had access to drug insurance will now find themselves with no coverage or, if coverage continues, with reduced financial means to afford copayments and ... Read More


W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More


The myth perpetuated by government and academics – and echoed in the media – is that the Patented Medicine Prices Review Board’s (PMPRB’s) current price control regime was somehow structured to go easy on patented drug prices in exchange for significant R&D commitments.  The upshot being that since the R&D ... Read More


The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers.  At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week.  Why ... Read More


PMPRB reporting season has been a semi-annual event for Canadian patentees for more than two decades. The mandatory reporting provides necessary information for PMPRB to fulfill its mandate: both to ensure patented drug prices are not excessive relative to those in other comparable jurisdictions, and to report to Parliament on ... Read More


The ongoing debate about repealing existing public and private drug programs and replacing them with a one-size-fits-all national pharmacare program returned to the headlines with the release of a wide-ranging report from the Parliamentary Budget Officer (PBO) which estimates the cost of a federally administered universal pharmacare plan. The PBO study ... Read More


Canada’s “health leaders” sponsoring the Open Pharma campaign should have checked with the Patented Medicine Prices Review Board (PMPRB) before advocating their ill-conceived and impractical proposal to have the federal government amend the Patented Medicines Regulations to force drug manufacturers to disclose payments to physicians via the PMPRB. An ... Read More


The release of the Patented Medicine Prices Review Board (PMPRB) Annual Report is delayed once again this year - so much for transparency and the PMPRB’s mission statement to “provide stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement ... Read More